Piper Jaffray Downgrades Achillion Pharmaceuticals (ACHN) to Neutral
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
William Blair Downgrades Achillion Pharmaceuticals (ACHN) to Market Perform
September 30, 2013 7:41 AM EDTWilliam Blair downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Outperform to Market Perform with a price target of $5.00.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on... More
BofA/Merrill Lynch Downgrades Achillion Pharmaceuticals (ACHN) to Underperform
September 30, 2013 6:45 AM EDTBofA/Merrill Lynch downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Underperform.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $7.24 yesterday, with a 52 week range of $6.12-$11.36.... More
JMP Securities Downgrades Achillion Pharmaceuticals (ACHN) to Market Perform
September 30, 2013 6:44 AM EDTJMP Securities downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $7.24 yesterday, with a 52 week range of $6.12-$11.36.... More
Achillion Pharma (ACHN) Says FDA Unable to Resolve Clinical Hold on Sovaprevir, Gives Pipeline Update
September 27, 2013 4:33 PM EDTAchillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today provided an update on development of compounds in its pipeline of therapies for the treatment of chronic hepatitis C virus, or HCV. Achillion today received a response from the U. S. Food and Drug Administration, or FDA, on the clinical hold related to sovaprevir, Achillion's NS3 protease inhibitor. The FDA response indicated that, while Achillion's submission addressed all issues noted in the FDA's June 29, 2013 letter, the FDA concluded that the removal of the clinical hold is not warranted.
"While we are disappointed that we... More
Achillion Pharmaceuticals (ACHN) Halted News Pending
September 27, 2013 4:14 PM EDTAchillion Pharmaceuticals (Nasdaq: ACHN) Halted News Pending... More